2. Search Result
Search Result
Results for "

cathepsin cleavable

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Peptides

5

Click Chemistry

1

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-20336
    Mc-Val-Cit-PABC-PNP
    Maximum Cited Publications
    6 Publications Verification

    Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate

    		 ADC Linker Others Inflammation/Immunology Cancer
    Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .
    Mc-Val-Cit-PABC-PNP
  • HY-145929
    MC-Val-Cit-PAB-Exatecan
    1 Publications Verification

    MC-Val-Cit-PAB-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.
    MC-Val-Cit-PAB-Exatecan
  • HY-112786
    MC-Val-Cit-PAB-MMAF
    5 Publications Verification

    Vc-MMAF

    		 Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .
    MC-Val-Cit-PAB-MMAF
  • HY-13240
    LY2886721
    2 Publications Verification

    		 Beta-secretase Neurological Disease
    LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
    LY2886721
  • HY-136547
    Boc-Val-Ala-PAB

    		ADC Linker Others
    Boc-Val-Ala-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate (ADCs) .
    Boc-Val-Ala-PAB
  • HY-153031
    Val-Cit-PAB-Exatecan

    Val-Cit-PAB-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .
    Val-Cit-PAB-Exatecan
  • HY-W071967
    Alloc-Val-Ala-pAB

    		ADC Linker Cancer
    Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
    Alloc-Val-Ala-pAB
  • HY-164278
    diABZI-V/C-Mal

    		STING Cathepsin Cancer
    diABZI-V/C-Mal is a STING agonist (with a STING EC50 of 314 nM in TH1 dual reporter cells) and a Cathepsin B substrate. diABZI-V/C-Mal activates STING, thereby triggering the IRF3 signaling pathway. diABZI-V/C-Mal is cleaved by Cathepsin B to regenerate diABZI-NH2 .
    diABZI-V/C-Mal
  • HY-142021
    Z-Leu-Arg-AMC

    		Cathepsin Parasite Infection Inflammation/Immunology
    Z-Leu-Arg-AMC is a fluorogenic peptide substrate for cysteine proteases (e.g., Cathepsin) (Ex=350 nm，Em=460 nm). Z-Leu-Arg-AMC is preferentially cleaved by Cathepsin K and S under weakly acidic conditions, while its hydrolysis relies on residual Cathepsin S activity at neutral pH. Z-Leu-Arg-AMC serves as a substrate for recombinant Sphenophorus levis Cathepsin L, falcipain-2, falcipain-3, berghepain-2, knowlepain-2, vivapain-2, as well as falcipain-2 chimeras and constructs. It enables quantitative detection of cysteine protease activity in human inflammatory bronchoalveolar lavage fluid via fluorescence generation. Z-Leu-Arg-AMC can be used in research related to pulmonary inflammatory diseases and malaria .
    Z-Leu-Arg-AMC
  • HY-149931
    BMV109

    		Fluorescent Dye Cancer
    BMV109 is a quenched probe that becomes fluorescent when cleaved and covalently bound by active cathepsin proteases. BMV109 can be exploited for tumor imaging .
    BMV109
  • HY-141860
    PSMA-Val-Cit-PAB-MMAE

    		PSMA Microtubule/Tubulin Reactive Oxygen Species (ROS) Cytochrome P450 Cancer
    PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .
    PSMA-Val-Cit-PAB-MMAE
  • HY-129362
    Phe-Lys(Fmoc)-PAB

    		ADC Linker Cancer
    Phe-Lys(Fmoc)-PAB is a cathepsin cleavable ADC linker used for the antibody-drug conjugates (ADCs) .
    Phe-Lys(Fmoc)-PAB
  • HY-P3012
    Cathepsin G

    		Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP Inflammation/Immunology
    Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .
    Cathepsin G
  • HY-W190913
    DBCO-PEG4-Val-Cit-PAB-PNP

    		ADC Linker Cancer
    DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.
    DBCO-PEG4-Val-Cit-PAB-PNP
  • HY-W591374
    DBCO-PEG4-Val-Ala-PAB-PNP

    		ADC Linker Cancer
    DBCO-PEG4-Val-Ala-PAB-PNP is a cleavable ADC linker. The Val-Ala linkers can be cleaved by Cathepsin B. The DBCO groups is commonly used for Click Chemistry reactions. PEG spacer improves the compound's aqueous solubility. PNP is a good leaving group.
    DBCO-PEG4-Val-Ala-PAB-PNP
  • HY-153031A
    Val-Cit-PAB-Exatecan TFA

    Val-Cit-PAB-DX8951 TFA

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) TFA is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan TFA is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .
    Val-Cit-PAB-Exatecan TFA
  • HY-131158
    DBCO-PEG3-Glu-VC-PABC-MMAF

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable DBCO-PEG3-Glu-VC-PABC. DBCO-PEG3-Glu-VC-PABC-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) .
    DBCO-PEG3-Glu-VC-PABC-MMAF
  • HY-129349
    Phe-Lys(Trt)-PAB

    		ADC Linker Cancer
    Phe-Lys(Trt)-PAB is a cathepsin cleavable ADC linker used for the antibody-drug conjugates (ADCs) .
    Phe-Lys(Trt)-PAB
  • HY-20336G
    Mc-Val-Cit-PABC-PNP

    		ADC Linker Cancer
    Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
    Mc-Val-Cit-PABC-PNP
  • HY-132973
    MC-Val-Cit-PAB-NH-C2-NH-Boc

    		ADC Linker Cancer
    MC-Val-Cit-PAB-NH-C2-NH-Boc is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    MC-Val-Cit-PAB-NH-C2-NH-Boc
  • HY-P5377
    Abz-HPGGPQ-EDDnp

    cathepsin K substrate

    		 Ser/Thr Protease Others
    Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)
    Abz-HPGGPQ-EDDnp
  • HY-W591479
    MC-Val-Ala-NHS ester

    		ADC Linker Cancer
    MC-Val-Ala-NHS ester is a cleavable ADC linker with a malimide group and an NHS ester group. The Val-Ala linkers can be cleaved by Cathepsin B. Maleimide group is reactive toward thiol groups. MC is reactive with thiol moieties. The NHS ester is able to react specifically and efficiently with amines (e.g. the side chain of lysine residues or aminosilane-coated surfaces) at neutral or slightly basic condition to form a covalent bond.
    MC-Val-Ala-NHS ester
  • HY-176810
    CDN prodrug-1

    		STING Cancer
    CDN prodrug-1 (Compound 2) is a STING ligand. CDN prodrug-1 consists of a cyclic dinucleotide (CDN) and a dialanine peptide linker. CDN prodrug-1 can be cleaved following internalization into endolysosomes by cathepsins and subsequently release the parent CDN. CDN prodrug-1 can be used for synthesis nanoparticles for drug delivery research .
    CDN prodrug-1
  • HY-48668
    AcLys-PABC-VC-Aur0101 intermediate-1

    		ADC Linker Cancer
    AcLys-PABC-VC-Aur0101 intermediate-1 is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate .
    AcLys-PABC-VC-Aur0101 intermediate-1
  • HY-W591373
    DBCO-PEG4-Val-Ala-PAB

    		ADC Linker Cancer
    DBCO-PEG4-Val-Ala-PAB is a cleavable ADC linker. The Val-Ala linkers can be cleaved by Cathepsin B. The DBCO groups is commonly used for Click Chemistry reactions. PEG spacer improves the compound's aqueous solubility.
    DBCO-PEG4-Val-Ala-PAB
  • HY-160756A
    Val-Cit-Exatecan TFA

    		Drug-Linker Conjugates for ADC Cancer
    Val-Cit-Exatecan TFA is an agent-linker conjugate for ADC. Val-Cit-Exatecan TFA is composed of a DNA topoisomerase I Exatecan (HY-13631) and a cathepsin cleavable ADC linker .
    Val-Cit-Exatecan TFA
  • HY-W800814
    Azido-PEG8-Amido-Val-Cit-PAB

    		ADC Linker Cancer
    Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.
    Azido-PEG8-Amido-Val-Cit-PAB
  • HY-W076556
    Alloc-Val-Ala-OH

    ((Allyloxy)carbonyl)-L-valyl-L-alanine

    		 Biochemical Assay Reagents Others
    Alloc-Val-Ala-OH (((Allyloxy)carbonyl)-L-valyl-L-alanine) is a building block in the synthesis of Tesirine, a clinical antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.
    Alloc-Val-Ala-OH
  • HY-13240A
    LY2886721 hydrochloride

    		Beta-secretase Neurological Disease
    LY2886721 hydrochloride is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
    LY2886721 hydrochloride
  • HY-171509
    Mal-N(Me)-C6-N(Me)-PNU-159682

    		Drug-Linker Conjugates for ADC Apoptosis Cancer
    Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27), an agent-linker conjugate for ADC, consists the ADC linker Mal-N(Me)-C6-N(Me) and a potent ADC cytotoxin PNU-159682. Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) selectively delivers the payload to CD46-expressing cells, where the linker is cleaved by cathepsin B to release PNU-159682, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 shows durable tumor regression in xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) .
    Mal-N(Me)-C6-N(Me)-PNU-159682
  • HY-160756
    Val-Cit-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
    Val-Cit-Exatecan
  • HY-185493
    Mal-VC-PAB-seco-CBI-PBD dimer

    		Drug-Linker Conjugates for ADC Cancer
    Mal-VC-PAB-seco-CBI-PBD dimer is a highly active drug-linker conjugate. Mal-VC-PAB-seco-CBI-PBD dimer integrates the DNA-damaging effects of two distinct types of compounds: seco-cyclopropabenzindoline (seco-CBI) and pyrrolobenzodiazepine (PBD). Mal-VC-PAB-seco-CBI-PBD dimer is linked via a valine-alanine (VC) linker cleavable by cathepsin B and achieves targeted delivery relying on monoclonal antibodies. Mal-VC-PAB-seco-CBI-PBD dimer is applicable for cancer research .
    Mal-VC-PAB-seco-CBI-PBD dimer

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: